CCO Treatment Updates
Current Research Directions in Glioblastoma Multiforme: Evolutions in Targeted Therapy
Current Treatment Options and the Need for Novel Therapeutics in Glioblastomas |
Module 1 of 3 |
|
Program Director: James J. Vredenburgh, MD
|
|
Patrick Y. Wen, MD, reviews current and emerging therapeutic strategies for newly diagnosed and recurrent glioblastoma multiforme.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss current approaches to the treatment of GBM including chemotherapy, surgery, and radiotherapy
- Recount research directions with targeted agents demonstrating investigational potential for the treatment of GBM
- Cite genetic factors affecting the pathogenesis and prognosis of GBM
- Explain challenges in the treatment of patients with recurrent GBM
- Summarize considerations in the use of anticonvulsant therapy for patients with GBM
|
Promising Investigational Directions: An Overview of Targeted Therapy in GBM |
Module 2 of 3 |
|
Program Director: James J. Vredenburgh, MD
|
|
Henry S. Friedman, MD, discusses promising investigational targeted therapies for glioblastoma multiforme.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss current approaches to the treatment of glioblastoma multiforme including chemotherapy, surgical and radiation therapeutic approaches
- Describe the molecular targets of glioblastoma multiforme
- Recount research directions with targeted agents demonstrating investigational potential for the treatment of glioblastoma multiforme
|
Expert Analysis: How Do Recent Data Impact Practical Management of Patients With GBM? |
Module 3 of 3 |
|
Program Director: James J. Vredenburgh, MD
 
- Henry S. Friedman, MD
- Patrick Y. Wen, MD
|
|
|
Expert faculty members discuss treating patients with gliomas in light of the recent data in investigational targeted therapies.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the current National Comprehensive Cancer Network guidelines for treatment for glioblastoma multiforme
- Describe the roles of bevacizumab and temozolomide in treating patients with glioblastoma multiforme
- Cite the challenges in incorporating new agents in the newly diagnosed setting and in combining these novel agents for glioblastoma multiforme
- Explain the impact of genetic heterogeneity on the selection of targeted therapy for glioblastoma multiforme
|
Slideset Module
Current Research Directions in Glioblastoma Multiforme: Evolutions in Targeted Therapy
|
Program Director: James J. Vredenburgh, MD
- James J. Vredenburgh, MD
- Henry S. Friedman, MD
- Patrick Y. Wen, MD
|
|
|
James J. Vredenburgh, MD, reviews the current treatment options and targeted therapies for newly diagnosed and recurrent glioblastoma multiforme.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss current approaches to the treatment of GBM including chemotherapy, surgery, and radiotherapy
- Recount research directions with targeted agents demonstrating investigational potential for the treatment of GBM
- Cite genetic factors affecting the pathogenesis and prognosis of GBM
- Explain challenges in the treatment of patients with recurrent GBM
|
Slideset: Current Research Directions in Glioblastoma Multiforme: Evolutions in Targeted Therapy
 |
|
James Vredenburgh, MD, reviews current treatment options and discusses novel approaches for GBM in the newly diagnosed and recurrent settings.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.76 MB
| Date posted: 12/17/2008
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|
|